# Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer

> **NCT00601926** · PHASE2 · TERMINATED · sponsor: **Paul Monk** · enrollment: 5 (actual)

## Conditions studied

- Kidney Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab

## Key facts

- **NCT ID:** NCT00601926
- **Lead sponsor:** Paul Monk
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02
- **Primary completion:** 2011-08
- **Final completion:** 2013-05
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Poor patient accrual. Attempts to open at other sites unsuccessful.
- **Last updated:** 2015-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00601926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00601926, "Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00601926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*